Discover and read the best of Twitter Threads about #amiorganics
Most recents (4)
AMI Organics
Stock has come out of a 70 weeks consolidation post Q4FY23 numbers.
Company has emphasized three things:
(1) Chinese chemical industry revival has min to no bearing on them
(2) Company never benefitted from Chinese plants shutting down.
Stock has come out of a 70 weeks consolidation post Q4FY23 numbers.
Company has emphasized three things:
(1) Chinese chemical industry revival has min to no bearing on them
(2) Company never benefitted from Chinese plants shutting down.
1/n
(3) Company is global leader in its key products with China & other geographies in the second & third spot.
Electrolyte Additives:
(1) Received approval from 06 customers worldwide
(2) Received plant scale trial commercial orders of few metric tons
(3) Expecting big order
(3) Company is global leader in its key products with China & other geographies in the second & third spot.
Electrolyte Additives:
(1) Received approval from 06 customers worldwide
(2) Received plant scale trial commercial orders of few metric tons
(3) Expecting big order
2/n
(4) Two more products developed & in advanced stages of validation.
Company has successfully signed long term LOIs & contracts with their big customers.
Company will now be doing 3 advanced intermediates for Fermion which will increase their contract manyfold.
(4) Two more products developed & in advanced stages of validation.
Company has successfully signed long term LOIs & contracts with their big customers.
Company will now be doing 3 advanced intermediates for Fermion which will increase their contract manyfold.
About -
Ami Organics Ltd (AOL)founded in 2004, is one of the leading pharmaceutical companies manufacturing different types of Advanced Pharmaceutical Intermediates, Active Pharmaceutical ingredients (API) for New Chemical Entities (NCE), KSM, agrochemicals and fine chemicals.
Ami Organics Ltd (AOL)founded in 2004, is one of the leading pharmaceutical companies manufacturing different types of Advanced Pharmaceutical Intermediates, Active Pharmaceutical ingredients (API) for New Chemical Entities (NCE), KSM, agrochemicals and fine chemicals.
Financial Summary -
Q4 FY22 (YoY)
Revenue were at ₹144 Cr ⬆️55%
EBITDA at ₹26 Cr ⬆️ 11%
PAT at ₹21 Cr ⬆️ 38%
Q4 FY22 (YoY)
Revenue were at ₹144 Cr ⬆️55%
EBITDA at ₹26 Cr ⬆️ 11%
PAT at ₹21 Cr ⬆️ 38%
#AmiOrganics Q3 2022 Concall Highlights 🧪🧪
Like & Retweet for better reach !
Operational Highlights
1. Revenue from operations for Q3FY22 grew by 53.5% YoY to ₹141.2Cr
Like & Retweet for better reach !
Operational Highlights
1. Revenue from operations for Q3FY22 grew by 53.5% YoY to ₹141.2Cr
2. Gross margin for the 9M FY22 improved to 48.8% higher by 238 bps when compared to 9M FY21 numbers
3. EBITDA stood at ₹30 Cr in Q3FY22 from ₹21.7 Cr in same period previous year translating a growth of 38% YoY
3. EBITDA stood at ₹30 Cr in Q3FY22 from ₹21.7 Cr in same period previous year translating a growth of 38% YoY
4. EBITDA has improved sharply but it has not yet reached its full potential
